Novo Nordisk: Pipeline Progress Collides With Pricing Reality
11.06.2026 - 07:05:10 | boerse-global.de
Novo Nordisk’s shares have been hammered, losing roughly 46% over the past twelve months and trading at a fraction of their 52-week high of €70.13. After closing at €37.09 on one session, the stock edged up 2.52% to €37.50 on the day the company unveiled fresh clinical data in New Orleans. Yet this modest bounce does little to mask the broader sell-off — the stock has fallen roughly 16% year-to-date, and the narrative has turned decisively bearish. The question is whether the market has overreacted to genuine structural challenges or is correctly pricing in a bleaker future.
The bears have ammunition. Pricing pressure in the US, intensifying competition from Eli Lilly, and a guidance cut for 2026 all weigh on sentiment. Eli Lilly’s Zepbound has already overtaken Novo Nordisk’s GLP-1 portfolio in market share, and a head-to-head comparison showed CagriSema delivering a 23% weight loss versus Zepbound’s 25.5%. That gap, combined with lower US selling prices flagged in recent quarterly results, has led analysts at Morgan Stanley to prefer the American rival. The stock now sits roughly 11% below its 200-day moving average of €41.51, and the RSI hovers around 48–50, suggesting a market that is exhausted but not yet capitulating.
However, beneath the surface of the sell-off, the pipeline is delivering. On June 5, Novo Nordisk presented data on Zenagamtide, a next-generation molecule targeting two specific receptors. After 36 weeks, patients lost up to 14.6% of their body weight. The drug will enter Phase 3 trials in the second half of 2026, and while it is years from market, the signal is clear: the company’s discovery engine is not stalled. The market barely reacted to the news, an oversight that supporters argue is too harsh.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
More immediately, CagriSema awaits a FDA decision in the fourth quarter of 2026. A positive outcome would mark the first fixed combination of its kind for weight loss and could restore some of the confidence that has evaporated. Separately, Novi Nordisk’s work in rare diseases is advancing. The Phase 3 trial of Etavopivat for sickle cell disease met all primary endpoints, cutting painful crises by 27% and producing a positive hemoglobin response in nearly half of patients. A first regulatory filing is planned by the end of the year, opening up a potential revenue stream in a market of roughly eight million patients worldwide, far removed from the brutal pricing wars in obesity.
The technical picture offers a mixed read. The stock has bounced off a low of €30.25 in March and now sits just above its 50-day moving average of €36.11, hinting at near-term stabilization. But the annualized volatility of over 34% underscores the lingering nervousness. The RSI reading of 48.7 (or 50.8 in another calculation) places the stock in a neutral zone, leaving room for a directional move either way. The chart is not signaling a bottom; it is signaling a painful re-rating that may still have further to run.
Management is not standing still. In May, the company raised its full-year guidance, citing stronger expectations for Wegovy HD sales in the US. It is also expanding direct-to-patient outreach and forging telemedicine partnerships to broaden access. These moves address the volume side of the equation but do little to resolve the margin pressure from lower realized prices. The capital markets day planned for September 21 in London is shaping up as the next major test. Investors will expect clear strategic answers on how the company intends to defend its leadership in a more competitive, lower-price environment.
The stock is not a broken business model. It is a high-quality company navigating commercial stress. The recent clinical wins — from Zenagamtide to Etavopivat — provide a scientific counterweight to the pricing headwinds, but they will not erase the market’s skepticism overnight. Novo Nordisk now has to prove it can sustain profitability at lower prices and fend off Eli Lilly’s encroachment. Until the London meeting delivers a credible roadmap, the share price is likely to remain caught between the promise of the pipeline and the reality of the pricing crunch.
Ad
Novo Nordisk Stock: New Analysis - 11 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
